1. Home
  2. MRK vs NVO Comparison

MRK vs NVO Comparison

Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

N/A

Current Price

$147.94

Market Cap

317.8B

Sector

Health Care

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$40.59

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRK
NVO
Founded
2000
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.8B
199.4B
IPO Year
1997
2001

Fundamental Metrics

Financial Performance
Metric
MRK
NVO
Price
$147.94
$40.59
Analyst Decision
Buy
Hold
Analyst Count
28
14
Target Price
★ $161.53
$45.74
AVG Volume (30 Days)
7.3M
★ 8.6M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
2.31%
★ 3.12%
EPS Growth
★ 8.01
N/A
EPS
N/A
★ N/A
Revenue
★ $65,011,000,000.00
N/A
Revenue This Year
$3.43
N/A
Revenue Next Year
$3.30
$1.30
P/E Ratio
★ N/A
$13.60
Revenue Growth
★ 1.31
N/A
52 Week Low
$91.49
$35.12
52 Week High
$157.00
$64.16

Technical Indicators

Market Signals
Indicator
MRK
NVO
Relative Strength Index (RSI) 52.24 53.41
Support Level $145.75 $37.61
Resistance Level $154.15 $41.41
Average True Range (ATR) 3.99 0.78
MACD 0.15 0.25
Stochastic Oscillator 59.32 52.84

Price Performance

Historical Comparison
MRK
NVO

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: